Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
65862-0391-10 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-30 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-66 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2010 In Use
65862-0391-02 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2024 In Use
65862-0391-05 65862-0391 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 12, 2024 In Use
46708-0730-31 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
46708-0730-36 46708-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
67296-0902-01 67296-0902 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
67296-0902-02 67296-0902 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 1, 2021 In Use
67296-0902-03 67296-0902 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
68001-0611-33 68001-0611 Zoledronic acid Zoledronic acid 5.0 mg/100mL Ancillary Therapy Bisphosphonate Intravenous May 3, 2024 In Use
68788-8433-01 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-03 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-06 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68788-8433-09 68788-8433 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral April 24, 2024 In Use
68071-2661-00 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-01 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-02 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-03 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68071-2661-05 68071-2661 PREDNISONE PREDNISONE 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral March 28, 2022 In Use
68788-8626-01 68788-8626 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral April 9, 2024 In Use
68788-8626-03 68788-8626 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral April 9, 2024 In Use
68788-8626-06 68788-8626 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral April 9, 2024 In Use
68788-8626-09 68788-8626 Estradiol Estradiol 0.5 mg/1 Hormonal Therapy Estrogen Oral April 9, 2024 In Use
68788-8651-01 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-02 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-03 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-05 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8651-06 68788-8651 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 29, 2024 In Use
68788-8663-01 68788-8663 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 13, 2024 In Use
68788-8663-02 68788-8663 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 13, 2024 In Use
68788-8663-03 68788-8663 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 13, 2024 In Use
68788-8663-04 68788-8663 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 13, 2024 In Use
68788-8663-05 68788-8663 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 13, 2024 In Use
68788-8663-08 68788-8663 PREDNISONE Prednisone 20.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 13, 2024 In Use
68788-8666-01 68788-8666 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 14, 2024 In Use
68788-8666-03 68788-8666 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral May 14, 2024 In Use
69539-0318-05 69539-0318 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
69539-0318-92 69539-0318 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
69539-0319-05 69539-0319 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
69539-0319-60 69539-0319 Abiraterone acetate Abiraterone 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral April 26, 2024 In Use
70377-0010-22 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0010-11 70377-0010 Everolimus EVEROLIMUS 2.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0011-22 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0011-11 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0011-23 70377-0011 Everolimus EVEROLIMUS 5.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
70377-0012-22 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use
70377-0012-11 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral June 8, 2023 In Use
70377-0012-23 70377-0012 Everolimus EVEROLIMUS 7.5 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral May 17, 2024 In Use
70377-0013-22 70377-0013 Everolimus EVEROLIMUS 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Oct. 1, 2021 In Use

Found 10,000 results in 4 milliseconds — Export these results